Tirzepatide for the treatment of adults living with concurrent type 1 diabetes and overweight or obesity (TZP-T1D): a double-blind, placebo-matched randomised controlled trial protocol

What Was Tested

Researchers studied Tirzepatide in this clinical study publication.

Tirzepatide, a dual agonist for glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors, shows promise in managing weight and glycaemic control in type 2 diabetes but is unexplored in the context of T1D.

Ethical approval has been obtained from the Northern Sydney Local Health District's Human Research Ethics Committee (approval ID #2024/ETH00180).

Who Took Part

The abstract describes 60 participants taking part.

The age groups tagged for this paper are teenagers, young adults, adults, middle-aged adults and older adults, both men and women.

Compliance, adverse events and medication interactions will be closely monitored, with adjustments made for tolerability.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Tirzepatide and who got the comparison, which limits bias.

As a double-blind Tirzepatide study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Tirzepatide group a baseline to be compared against.

The primary outcome is the change in body weight (%).

Secondary outcome measures will be analysed by Student's t-test.

What Was Measured

PubMed files the paper under topics including Diabetes Mellitus, Type 1, Obesity, Overweight, Tirzepatide, Glycated Hemoglobin, Randomized Controlled Trials as Topic and Hypoglycemic Agents.

Author keywords: Diabetes & endocrinology, General diabetes and Other metabolic, e.g. iron, porphyria.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Tirzepatide in 60 participants.

The publication is from 2025 (BMJ open), a journal based in England.

More context: the Tirzepatide compound page, all human trials.